Ballicules.com

Pentoxifylline

TRENTAL

What it isPDE-inhibiting xanthine that improves red-cell deformability; intermittent claudication and off-label venous ulcers.

Why this oneIt reduces blood viscosity, a mechanism unlike other drugs used for claudication.

What limits itWalking benefit is modest and inconsistent; GI intolerance is common, and anticoagulants increase bleeding concern.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Intermittent claudicationadult400 mg TID with meals

Renal Severe impairment (CrCl <30 mL/min): reduce to 400 mg once daily.

Hepatic Undefined - dosing information cannot be provided for hepatic impairment.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Animal studies show no fetal malformation; use in pregnancy only if benefit justifies risk.

Lactation Undefined

NO BOXED WARNINGS

Principal riskGI upset; bleeding risk with anticoagulants

Cost, est. cash$5–$150/month

Generic entry1997

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Pentoxifylline ballicule

Pentoxifylline ballicule: receptor binding, kinetics and half-life diagram

Open Pentoxifylline in the interactive console ↗

Memory aids: mascots and interaction avatars

Pentoxifylline TRENTAL mascot mnemonic cartoon
“Trent’s Pinto felines”
Trent Alexander-Arnold, Liverpool Football Club
RBC headlights → blood viscosity reducer
Pentoxifylline CYP1A2 substrate avatar
CYP1A2 substrate

Open Pentoxifylline in the interactive console ↗